^
    over1year
    RAS status in circulating-tumor DNA after chemotherapy in RAS-mutant mCRC: The RASMEX study (JACCRO CC-17) (ESMO-GI 2023)
    Our prospective observational study revealed not the least proportion of patients with no RAS mutations in ctDNA after 1st- or 2nd-line treatment in RAS mutant mCRC. Further analysis will be performed to evaluate the efficacy of anti-EGFR antibody treatment for patients with no RAS mutation in ctDNA after standard chemotherapy.
    Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • RAS mutation • RAS wild-type • KRAS exon 2 mutation • NRAS exon 4 mutation • KRAS exon 3 mutation
    |
    OncoBEAM RAS CRC kit
    over4years
    A New Era of Colorectal Cancer Treatment Being Led by a Precise Analysis of Somatic Mutational Profiles Including RAS, BRAF Mutation and Microsatellite Instability Status (PubMed, Gan To Kagaku Ryoho)
    Since these somatic mutational profiles in colorectal cancer cells are measured to determine the propriety of administration of a particular medicine, the results must be appropriately reflected in therapy for each patient. In this review, I will summarize the feature of clinical characteristics belonging to each somatic mutational profile commonly observed in colorectal cancer, and discuss howsuch somatic mutational profiles including RAS, BRAF mutation, and microsatellite instability status bring us to a newera of colorectal cancer.
    Review • Journal • Microsatellite Instability
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • BRAF mutation • NRAS mutation • BRAF V600 • KRAS exon 2 mutation • NRAS exon 4 mutation